Role of cytokines as a double-edged sword in sepsis

In Vivo

Volumn 27, Issue 6, 2013, Pages 669-684

  Chaudhry, Hina ^a   Zhou, Juhua ^a,b   Zhong, Yin ^a   Ali, Mir Mustafa ^a   Mcguire, Franklin ^a   Nagarkatti, Prakash S ^a   Nagarkatti, Mitzi ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b LUDONG UNIVERSITY   (China)

Author keywords

Anti inflammatory; Biomarker; Cytokine; Pro inflammatory; Review; Sepsis; Signaling pathway

Indexed keywords

ANDROSTENEDIOL; BIOLOGICAL MARKER; CORTICOSTEROID; CYCLOHEXENE DERIVATIVE; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 35; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY IL 1; NEUTRALIZING ANTIBODY IL 17; NEUTRALIZING ANTIBODY TNF ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; ULINASTATIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL (TOPIC); CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; DISEASE SEVERITY; FATALITY; GENETIC POLYMORPHISM; GENOTYPE; HEMODIAFILTRATION; HUMAN; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFECTION; INFLAMMATION; MEDLINE; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANTI-INFLAMMATORY; BIOMARKER; CYTOKINE; PRO-INFLAMMATORY; REVIEW; SEPSIS; SIGNALING PATHWAY;

ANIMALS; BIOLOGICAL MARKERS; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION MEDIATORS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEPSIS; SIGNAL TRANSDUCTION;

EID: 84892735965     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. Rittirsch D, Flierl MA and Ward PA: Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8(10): 776-787, 2008.
2. Studnek JR, Artho MR, Garner CL Jr. and Jones AE: The impact of emergency medical services on the ed care of severe sepsis. Am J Emerg med 30(1): 51-56, 2012.
3. Hanisch E, Brause R, Paetz J and Arlt B: Review of a large clinical series: Predicting death for patients with abdominal septic shock. J Intensive Care Med 26(1): 27-33, 2011.
4. Becker KL, Snider R and Nylen ES: Procalcitonin in sepsis and systemic inflammation: A harmful biomarker and a therapeutic target. Br J Pharmacol 159(2): 253-264, 2010.
5. Melamed A and Sorvillo FJ: The burden of sepsis-associated mortality in the united states from 1999 to 2005: An analysis of multiple-cause-of-death data. Crit Care 13(1): R28, 2009.
6. Unsinger J, McGlynn M, Kasten KR, Hoekzema AS, Watanabe E, Muenzer JT, McDonough JS, Tschoep J, Ferguson TA, McDunn JE, Morre M, Hildeman DA, Caldwell CC and Hotchkiss RS: Il-7 promotes t cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol 184(7): 3768-3779, 2010.
7. Brun-Buisson C: Epidemiology of severe sepsis. Presse Med 35(3): 513-520, 2006.
8. Le Gall JR, Alberti C and Brun Buisson C: Epidemiology of infection and sepsis in intensive care unit patients. Bull Acad Natl Med 188(7): 1115-1125, 2004.
9. Russell JA: Management of sepsis. N Eng J Med 355(16): 1699-1713, 2006.
10. Meakins JL, Pietsch JB, Bubenick O, Kelly R, Rode H, Gordon J and MacLean LD: Delayed hypersensitivity: Indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg 186(3): 241-250, 1977.
11. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD, 2nd, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM and Hotchkiss RS: Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306(23): 2594-2605, 2011.
12. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG and Karl IE: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27(7): 1230-1251, 1999.
13. Mera S, Tatulescu D, Cismaru C, Bondor C, Slavcovici A, Zanc V, Carstina D and Oltean M: Multiplex cytokine profiling in patients with sepsis. APMIS 119(2): 155-163, 2011.
14. Jones SA, Scheller J and Rose-John S: Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121(9): 3375-3383, 2011.
15. Lukaszewicz M, Mroczko B and Szmitkowski M: Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn 117(5-6): 247-251, 2007 (in Polish).
16. Patterson CC, Smith AE, Yarnell JW, Rumley A, Ben-Shlomo Y and Lowe GD: The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: The caerphilly study. Atherosclerosis 209(2): 551-557, 2010.
17. Ishihara K and Hirano T: IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13(4-5): 357-368, 2002.
18. Gouel-Cheron A, Allaouchiche B, Guignant C, Davin F, Floccard B and Monneret G: Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: A powerful association to predict the development of sepsis after major trauma. PloS one 7(3): e33095, 2012.
19. Wu HP, Chen CK, Chung K, Tseng JC, Hua CC, Liu YC, Chuang DY and Yang CH: Serial cytokine levels in patients with severe sepsis. Inflamm Res 58(7): 385-393, 2009.
20. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL and Angus DC: Understanding the inflammatory cytokine response in pneumonia and sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 167(15): 1655-1663, 2007.
21. Kumar AT, Sudhir U, Punith K, Kumar R, Ravi Kumar VN and Rao MY: Cytokine profile in elderly patients with sepsis. Ind J Crit Care Med 13(2): 74-78, 2009.
22. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, Chan SY, Roczniak S and Shanafelt AB: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270(45): 27348-27357, 1995.
23. Lee YS, Bak EJ, Kim M, Park W, Seo JT and Yoo YJ: Induction of IL-8 in periodontal ligament cells by H2O2. J Microbiol 46(5): 579-584, 2008.
24. Glowacka E, Lewkowicz P, Rotsztejn H and Zalewska A: IL-8, IL-12 and IL-10 cytokines generation by neutrophils, fibroblasts and neutrophils- fibroblasts interaction in psoriasis. Adv Med Sci 55(2): 254-260, 2010.
25. Livaditi O, Kotanidou A, Psarra A, Dimopoulou I, Sotiropoulou C, Augustatou K, Papasteriades C, Armaganidis A, Roussos C, Orfanos SE and Douzinas EE: Neutrophil CD64 expression and serum IL-8: Sensitive early markers of severity and outcome in sepsis. Cytokine 36(5-6): 283-290, 2006.
26. + T cells through IL-12 produced by listeria-induced macrophages. Science 260(5107): 547-549, 1993.
27. Seder RA, Kelsall BL and Jankovic D: Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease. J Immunol 157(7): 2745-2748, 1996.
28. Hu Y, Shen F, Crellin NK and Ouyang W: The IL-17 pathway as a major therapeutic target in autoimmune diseases. Ann NY Acad Sci 1217: 60-76, 2011.
29. Shahrara S, Pickens SR, Mandelin AM, 2nd, Karpus WJ, Huang Q, Kolls JK and Pope RM: IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol 184(8): 4479-4487, 2010.
30. Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, Kuzlan-Pawlaczyk M, Wisniewska J, Polubinska A, Friess H, Gahl GM, Frei U and Jorres A: IL-17 stimulates intraperitoneal neutrophil infiltration through the release of gro alpha chemokine from mesothelial cells. J Immunol 165(10): 5814-5821, 2000.
31. Costa VS, Mattana TC and da Silva ME: Unregulated IL-23/IL-17 immune response in autoimmune diseases. Diabetes Res Clin Pract 88(3): 222-226, 2010.
32. Reynolds JM, Angkasekwinai P and Dong C: IL-17 family member cytokines: Regulation and function in innate immunity. Cytokine Growth Factor Rev 21(6): 413-423, 2010.
33. Chakir J, Shannon J, Molet S, Fukakusa M, Elias J, Laviolette M, Boulet LP and Hamid Q: Airway remodeling-associated mediators in moderate to severe asthma: Effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol 111(6): 1293-1298, 2003.
34. Wang YH and Liu YJ: The IL-17 cytokine family and their role in allergic inflammation. Curr Opin Immunol 20(6): 697-702, 2008.
35. Crome SQ, Wang AY and Levings MK: Translational minireview series on Th17 cells: Function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol 159(2): 109-119, 2010.
36. Aggarwal S and Gurney AL: IL-17: Prototype member of an emerging cytokine family. J Leuk Biol 71(1): 1-8, 2002.
37. van de Veerdonk FL, Kullberg BJ, Verschueren IC, Hendriks T, van der Meer JW, Joosten LA and Netea MG: Differential effects of IL-17 pathway in disseminated candidiasis and zymosan-induced multiple organ failure. Shock 34(4): 407-411, 2010.
38. Freitas A, Alves-Filho JC, Victoni T, Secher T, Lemos HP, Sonego F, Cunha FQ and Ryffel B: IL-17 receptor signaling is required to control polymicrobial sepsis. J Immunol 182(12): 7846-7854, 2009.
39. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC and Bozza PT: Cytokine profiles as markers of disease severity in sepsis: A multiplex analysis. Crit Care 11(2): R49, 2007.
40. Boraschi D and Dinarello CA: IL-18 in autoimmunity: Review. Eur Cytokine Netw 17(4): 224-252, 2006.
41. Rau M, Schiller M, Krienke S, Heyder P, Lorenz H and Blank N: Clinical manifestations but not cytokine profiles differentiate adult-onset still's disease and sepsis. J Rheumatol 37(11): 2369-2376, 2010.
42. Tschoeke SK, Oberholzer A and Moldawer LL: Interleukin-18: A novel prognostic cytokine in bacteria-induced sepsis. Crit Care Med 34(4): 1225-1233, 2006.
43. Schoenborn JR and Wilson CB: Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96: 41-101, 2007.
44. Stassen NA, Leslie-Norfleet LA, Robertson AM, Eichenberger MR and Polk HC Jr.: Interferon-gamma gene polymorphisms and the development of sepsis in patients with trauma. Surgery 132(2): 289-292, 2002.
45. Romero CR, Herzig DS, Etogo A, Nunez J, Mahmoudizad R, Fang G, Murphey ED, Toliver-Kinsky T and Sherwood ER: The role of interferon-gamma in the pathogenesis of acute intra-abdominal sepsis. J Leuk Biol 88(4): 725-735, 2010.
46. Weighardt H, Heidecke CD, Emmanuilidis K, Maier S, Bartels H, Siewert JR and Holzmann B: Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production. Surgery 127(3): 309-315, 2000.
47. Ono S, Ueno C, Aosasa S, Tsujimoto H, Seki S and Mochizuki H: Severe sepsis induces deficient interferon-gamma and interleukin-12 production, but interleukin-12 therapy improves survival in peritonitis. Am J Surg 182(5): 491-497, 2001.
48. Ertel W, Morrison MH, Ayala A, Dean RE and Chaudry IH: Interferon-gamma attenuates hemorrhage-induced suppression of macrophage and splenocyte functions and decreases susceptibility to sepsis. Surgery 111(2): 177-187, 1992.
49. Hamilton JA: GM-CSF in inflammation and autoimmunity. Trends Immunol 23(8): 403-408, 2002.
50. Hamilton JA and Anderson GP: GM-CSF biology. Growth Factors 22(4): 225-231, 2004.
51. Lendemans S, Kreuzfelder E, Waydhas C, Schade FU and Flohe S: Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma. Inflamm Res 56(1): 38-44, 2007.
52. Orozco H, Arch J, Medina-Franco H, Pantoja JP, Gonzalez QH, Vilatoba M, Hinojosa C, Vargas-Vorackova F and Sifuentes-Osornio J: Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: A randomized, double-blind, placebo-controlled clinical trial. Arch Surg 141(2): 150-153, 2006.
53. Bo L, Wang F, Zhu J, Li J and Deng X: Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: A meta-analysis. Crit Care 15(1): R58, 2011.
54. Wallach D: Cell death induction by TNF: A matter of self control. Trends Biochem Sci 22(4): 107-109, 1997.
55. Scheringa M and Marquet RL: TNF: A brief review with emphasis on its antitumor activity. Biotherapy 2(3): 275-281, 1990.
56. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK and Lanctot KL: A meta-analysis of cytokines in major depression. Biol Psychiatry 67(5): 446-457, 2010.
57. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J and Herrmann N: A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 68 (10): 930-941, 2010.
58. Locksley RM, Killeen N and Lenardo MJ: The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104(4): 487-501, 2001.
59. Huang W, Tang Y and Li L: HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine 51(2): 119-126, 2010.
60. London NR, Zhu W, Bozza FA, Smith MC, Greif DM, Sorensen LK, Chen L, Kaminoh Y, Chan AC, Passi SF, Day CW, Barnard DL, Zimmerman GA, Krasnow MA and Li DY: Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med 2(23): 23ra19, 2010.
61. Opal SM and DePalo VA: Anti-inflammatory cytokines. Chest 117(4): 1162-1172, 2000.
62. Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S and Barrett RW: A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 386(6621): 194-200, 1997.
63. Dinarello CA: Induction of interleukin-1 and interleukin-1 receptor antagonist. Semin Oncol 24(3 Suppl 9): S9-81-S89-93, 1997.
64. Alexander HR, Doherty GM, Venzon DJ, Merino MJ, Fraker DL and Norton JA: Recombinant interleukin-1 receptor antagonist (IL-1Ra): Effective therapy against Gram-negative sepsis in rats. Surgery 112 (2): 188-193, 1992.
65. Kay AB, Barata L, Meng Q, Durham SR and Ying S: Eosinophils and eosinophil-associated cytokines in allergic inflammation. Int Arch Allergy Immunol 113(1-3): 196-199, 1997.
66. Song GY, Chung CS, Chaudry IH and Ayala A: IL-4-induced activation of the Stat6 pathway contributes to the suppression of cell-mediated immunity and death in sepsis. Surgery 128(2): 133-138, 2000.
67. Surbatovic M, Filipovic N, Radakovic S, Stankovic N and Slavkovic Z: Immune cytokine response in combat casualties: Blast or explosive trauma with or without secondary sepsis. Mil Med 172(2): 190-195, 2007.
68. Hultgren O, Kopf M and Tarkowski A: Outcome of Staphylococcus aureus -triggered sepsis and arthritis in IL-4-deficient mice depends on the genetic background of the host. Eur J Immunol 29(8): 2400-2405, 1999.
69. Gogos CA, Drosou E, Bassaris HP and Skoutelis A: Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options. J Infect Dis 181(1): 176-180, 2000.
70. Neddermann P, Graziani R, Ciliberto G and Paonessa G: Functional expression of soluble human interleukin-11 (IL-11) receptor alpha and stoichiometry of in vitro IL-11 receptor complexes with gp130. J Biol Chem 271(48): 30986-30991, 1996.
71. Hill GR, Cooke KR, Teshima T, Crawford JM, Keith JC Jr., Brinson YS, Bungard D and Ferrara JL: Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 102(1): 115-123, 1998.
72. Chang M, Williams A, Ishizawa L, Knoppel A, van de Ven C and Cairo MS: Endogenous interleukin-11 (IL-11) expression is increased and prophylactic use of exogenous IL-11 enhances platelet recovery and improves survival during thrombocytopenia associated with experimental group B streptococcal sepsis in neonatal rats. Blood Cells Mol Dis 22(1): 57-67, 1996.
73. Opal SM, Keith JC Jr., Jhung J, Palardy JE, Parejo N, Marchese E and Maganti V: Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis. J Infect Dis 187(1): 70-76, 2003.
74. Wynn TA: IL-13 effector functions. Annu Rev Immunol 21: 425-456, 2003.
75. Callard RE, Matthews DJ and Hibbert L: IL-4 and IL-13 receptors: Are they one and the same? Immunol Today 17(3): 108-110, 1996.
76. de Waal Malefyt R, Figdor CG, Huijbens R, Mohan-Peterson S, Bennett B, Culpepper J, Dang W, Zurawski G and de Vries JE: Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 151(11): 6370-6381, 1993.
77. Muchamuel T, Menon S, Pisacane P, Howard MC and Cockayne DA: IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: Correlation with down-modulation of TNF-alpha, IFN-gamma, and IL-12 production. J Immunol 158(6): 2898-2903, 1997.
78. Cao YZ, Tu YY, Chen X, Wang BL, Zhong YX and Liu MH: Protective effect of ulinastatin against murine models of sepsis: Inhibition of TNF-alpha and IL-6 and augmentation of IL-10 and IL-13. Exp Toxicol Pathol 64(6): 543-547, 2012.
79. van der Poll T, de Waal Malefyt R, Coyle SM and Lowry SF: Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: Sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 175(1): 118-122, 1997.
80. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS and Vignali DA: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169): 566-569, 2007.
81. Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, Murray PJ and Vignali DA: The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 13(3): 290-299, 2012.
82. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB and Liew FY: IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37(11): 3021-3029, 2007.
83. Chaturvedi V, Collison LW, Guy CS, Workman CJ and Vignali DA: Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 186(12): 6661-6666, 2011.
84. Ayala A, Knotts JB, Ertel W, Perrin MM, Morrison MH and Chaudry IH: Role of interleukin 6 and transforming growth factor-beta in the induction of depressed splenocyte responses following sepsis. Arch Surg 128(1): 89-94, 1993.
85. Ahmad S, Choudhry MA, Shankar R and Sayeed MM: Transforming growth factor-beta negatively modulates T-cell responses in sepsis. FEBS Lett 402(2-3): 213-218, 1997.
86. Pusterla N, Magdesian KG, Mapes S and Leutenegger CM: Expression of molecular markers in blood of neonatal foals with sepsis. Am J Vet Res 67(6): 1045-1049, 2006.
87. Knapp S, Thalhammer F, Locker GJ, Laczika K, Hollenstein U, Frass M, Winkler S, Stoiser B, Wilfing A and Burgmann H: Prognostic value of MIP-1 alpha, TGF-beta 2, sELAM-1, and sVCAM-1 in patients with Gram-positive sepsis. Clin Immunol Immunopathol 87(2): 139-144, 1998.
88. Arnalich F, Garcia-Palomero E, Lopez J, Jimenez M, Madero R, Renart J, Vazquez JJ and Montiel C: Predictive value of nuclear factor kappab activity and plasma cytokine levels in patients with sepsis. Infect Immun 68(4): 1942-1945, 2000.
89. Liu SF and Malik AB: Nf-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physio Lung Cell Mol Physiol 290(4): L622-L645, 2006.
90. Finnerty CC, Przkora R, Herndon DN and Jeschke MG: Cytokine expression profile over time in burned mice. Cytokine 45(1): 20-25, 2009.
91. Ulloa L and Tracey KJ: The "cytokine profile": A code for sepsis. Trends Mol Med 11(2): 56-63, 2005.
92. Finnerty CC, Herndon DN, Chinkes DL and Jeschke MG: Serum cytokine differences in severely burned children with and without sepsis. Shock 27(1): 4-9, 2007.
93. Campos DP, Silva MV, Machado JR, Castellano LR, Rodrigues V and Barata CH: Early-onset neonatal sepsis: Cord blood cytokine levels at diagnosis and during treatment. J Pediatr 86(6): 509-514, 2010.
94. Abdelhamid AE, Chuang SL, Hayes P and Fell JM: In vitro cow's milk protein-specific inflammatory and regulatory cytokine responses in preterm infants with necrotizing enterocolitis and sepsis. Pediatr Res 69(2): 165-169, 2011.
95. Opal SM, Girard TD and Ely EW: The immunopathogenesis of sepsis in elderly patients. Clin Infect Dis 41(Suppl 7): S504-512, 2005.
96. Castle S, Uyemura K, Wong W, Modlin R and Effros R: Evidence of enhanced type 2 immune response and impaired upregulation of a type 1 response in frail elderly nursing home residents. Mech Ageing Dev 94(1-3): 7-16, 1997.
97. Saito H, Sherwood ER, Varma TK and Evers BM: Effects of aging on mortality, hypothermia, and cytokine induction in mice with endotoxemia or sepsis. Mech Ageing Dev 124(10-12): 1047-1058, 2003.
98. Opal SM: Endotoxin and cytokine detection systems as biomarkers for sepsis-induced renal injury. Contrib Nephrol 156: 220-226, 2007.
99. Krzystek-Korpacka M, Mierzchala M, Neubauer K, Durek G and Gamian A: Midkine, a multifunctional cytokine, in patients with severe sepsis and septic shock: A pilot study. Shock 35(5): 471-477, 2011.
100. Yousef AA, Amr YM and Suliman GA: The diagnostic value of serum leptin monitoring and its correlation with tumor necrosis factor-alpha in critically ill patients: A prospective observational study. Crit Care 14(2): R33, 2010.
101. Charles PE, Ladoire S, Aho S, Quenot JP, Doise JM, Prin S, Olsson NO and Blettery B: Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria. BMC Infect Dis 8: 38, 2008.
102. Nyamande K and Lalloo UG: Serum procalcitonin distinguishes cap due to bacteria, mycobacterium tuberculosis and pjp. Int J Tuberc Lung Dis 10(5): 510-515, 2006.
103. Balc IC, Sungurtekin H, Gurses E, Sungurtekin U and Kaptanoglu B: Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 7(1): 85-90, 2003.
104. Moretti D, Ramirez MM, Settecase CJ, Bagilet DH and Quaglino MB: Usefulness of procalcitonin upon admission to intensive care in the diagnosis and prognosis of sepsis. Med Intensiva 37(3): 156-162, 2013.
105. Riedel S: Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis 73(3): 221-227, 2012.
106. Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, Moretti E, Nguyen HB, Gunnerson KJ, Milzman D, Gaieski DF, Goyal M, Cairns CB, Ngo L and Rivers EP: A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med 37(1): 96-104, 2009.
107. Kurt AN, Aygun AD, Godekmerdan A, Kurt A, Dogan Y and Yilmaz E: Serum IL-1beta, IL-6, IL-8, and TNF-alpha levels in early diagnosis and management of neonatal sepsis. Mediators Inflamm 2007: 31397, 2007.
108. Bachert C and Geveart P: Effect of intranasal corticosteroids on release of cytokines and inflammatory mediators. Allergy 54(Suppl 57): 116-123, 1999.
109. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, Keh D, Kupfer Y, Oppert M and Meduri GU: Corticosteroids in the treatment of severe sepsis and septic shock in adults: A systematic review. JAMA 301(22): 2362-2375, 2009.
110. Hirasawa H, Oda S and Matsuda K: Continuous hemodiafiltration with cytokine-adsorbing hemofilter in the treatment of severe sepsis and septic shock. Contrib Nephrol 156: 365-370, 2007.
111. Nakamura M, Oda S, Sadahiro T, Hirayama Y, Watanabe E, Tateishi Y, Nakada TA and Hirasawa H: Treatment of severe sepsis and septic shock by chdf using a pmma membrane hemofilter as a cytokine modulator. Contrib Nephrol 166: 73-82, 2010.
112. Zagli G, Bonizzoli M, Spina R, Cianchi G, Pasquini A, Anichini V, Matano S, Tarantini F, Di Filippo A, Maggi E and Peris A: Effects of hemoperfusion with an immobilized polymyxin-B fiber column on cytokine plasma levels in patients with abdominal sepsis. Minerva Anestesiol 76(6): 405-412, 2010.
113. Suzuki T, Shimizu T, Szalay L, Choudhry MA, Rue LW, 3rd, Bland KI and Chaudry IH: Androstenediol ameliorates alterations in immune cells cytokine production capacity in a two-hit model of trauma-hemorrhage and sepsis. Cytokine 34(1-2): 76-84, 2006.
114. Dinarello CA: The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 163(6): 1177-1184, 1991.
115. Clark MA, Plank LD, Connolly AB, Streat SJ, Hill AA, Gupta R, Monk DN, Shenkin A and Hill GL: Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis - a randomized, clinical trial. Crit Care Med 26(10): 1650-1659, 1998.
116. Dinarello CA: Proinflammatory cytokines. Chest 118(2): 503-508, 2000.
117. Flierl MA, Rittirsch D, Gao H, Hoesel LM, Nadeau BA, Day DE, Zetoune FS, Sarma JV, Huber-Lang MS, Ferrara JL and Ward PA: Adverse functions of IL-17A in experimental sepsis. FASEB J 22(7): 2198-2205, 2008.
118. White M, Lawless MW, O'Dwyer MJ, Grealy R, Connell BO, Stordeur P, Kelleher D, McManus R and Ryan T: Transforming growth factor beta-1 and interleukin-17 gene transcription in peripheral blood mononuclear cells and the human response to infection. Cytokine 50(3): 322-327, 2010.
119. Bosmann M and Ward PA: Therapeutic potential of targeting IL-17 and IL-23 in sepsis. Clin Transl Med 1(4): 1-5, 2012.
120. Dolinay T, Kim YS, Howrylak J, Hunninghake GM, An CH, Fredenburgh L, Massaro AF, Rogers A, Gazourian L, Nakahira K, Haspel JA, Landazury R, Eppanapally S, Christie JD, Meyer NJ, Ware LB, Christiani DC, Ryter SW, Baron RM and Choi AM: Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med 185(11): 1225-1234, 2012.
121. Yamada M, Ichikawa T, Ii M, Itoh K, Tamura N and Kitazaki T: Novel cyclohexene derivatives as anti-sepsis agents: Synthetic studies and inhibition of no and cytokine production. Bioorg Med Chem 16(7): 3941-3958, 2008.
122. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, Reinke P and Volk HD: Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: A double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 180(7): 640-648, 2009.
123. Trapnell BC: A novel biomarker-guided immunomodulatory approach for the therapy of sepsis. Am J Respir Crit Care Med 180(7): 585-586, 2009.
124. Hiraki S, Ono S, Kinoshita M, Tsujimoto H, Takahata R, Miyazaki H, Saitoh D, Seki S and Hase K: Neutralization of IL-10 restores the downregulation of IL-18 receptor on natural killer cells and interferon-gamma production in septic mice, thus leading to an improved survival. Shock 37(2): 177-182, 2012.
125. + regulatory T-cells in septic mice, thereby leading to an improved survival. Surgery 151(2): 313-322, 2012.
126. Comim CM, Vilela MC, Constantino LS, Petronilho F, Vuolo F, Lacerda-Queiroz N, Rodrigues DH, da Rocha JL, Teixeira AL, Quevedo J and Dal-Pizzol F: Traffic of leukocytes and cytokine up-regulation in the central nervous system in sepsis. Intensive Care Med 37(4): 711-718, 2011.
127. O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE and Ward AC: Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol 44(10): 2497-2506, 2007.
128. Hosoi T, Okuma Y, Kawagishi T, Qi X, Matsuda T and Nomura Y: Bacterial endotoxin induces STAT3 activation in the mouse brain. Brain Res 1023(1): 48-53, 2004.
129. Cho ML, Kang JW, Moon YM, Nam HJ, Jhun JY, Heo SB, Jin HT, Min SY, Ju JH, Park KS, Cho YG, Yoon CH, Park SH, Sung YC and Kim HY: STAT3 and NF-kappab signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 176(9): 5652-5661, 2006.
130. Pena G, Cai B, Liu J, van der Zanden EP, Deitch EA, de Jonge WJ and Ulloa L: Unphosphorylated STAT3 modulates alpha 7 nicotinic receptor signaling and cytokine production in sepsis. Eur J Immunol 40(9): 2580-2589, 2010.
131. Wen H, Lei Y, Eun SY and Ting JP: Plexin-A4-semaphorin 3A signaling is required for Toll-like receptor- and sepsis-induced cytokine storm. J Exp Med 207(13): 2943-2957, 2010.
132. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, Enkemann S, Jove R and Haura EB: Stat3 regulates genes common to both wound healing and cancer. Oncogene 24(21): 3397-3408, 2005.
133. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G and Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374(Pt 1): 1-20, 2003.
134. Donnelly RP, Dickensheets H and Finbloom DS: The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 19(6): 563-573, 1999.
135. Song GY, Chung CS, Schwacha MG, Jarrar D, Chaudry IH and Ayala A: Splenic immune suppression in sepsis: A role for IL-10-induced changes in P38 MAPK signaling. J Surg Res 83(1): 36-43, 1999.
136. Huang G, Shi LZ and Chi H: Regulation of JNK and p38 MAPK in the immune system: Signal integration, propagation and termination. Cytokine 48(3): 161-169, 2009.
137. Zhang J, Qian X, Ning H, Eickhoff CS, Hoft DF and Liu J: Transcriptional suppression of IL-27 production by Mycobacterium tuberculosis-activated p38 MAPK via inhibition of AP-1 binding. J Immunol 186(10): 5885-5895, 2011.
138. Venuprasad K, Elly C, Gao M, Salek-Ardakani S, Harada Y, Luo JL, Yang C, Croft M, Inoue K, Karin M and Liu YC: Convergence of Itch-induced ubiquitination with MEKK1-JNK signaling in Th2 tolerance and airway inflammation. J Clin Invest 116(4): 1117-1126, 2006.
139. Gaur U and Aggarwal BB: Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 66(8): 1403-1408, 2003.
140. Motoyama S, Miura M, Hinai Y, Maruyama K, Usami S, Nakatsu T, Saito H, Minamiya Y, Murata K, Suzuki T and Ogawa J: Interferon-gamma 874A>T genetic polymorphism is associated with infectious complications following surgery in patients with thoracic esophageal cancer. Surgery 146(5): 931-938, 2009.
141. Tischendorf JJ, Yagmur E, Scholten D, Vidacek D, Koch A, Winograd R, Gressner AM, Trautwein C, Wasmuth HE and Lammert F: The interleukin-6 (IL-6)-174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL-6. Int J Immunogenet 34(6): 413-418, 2007.
142. Accardo Palumbo A, Forte GI, Pileri D, Vaccarino L, Conte F, D'Amelio L, Palmeri M, Triolo A, D'Arpa N, Scola L, Misiano G, Milano S and Lio D: Analysis of IL-6, IL-10 and IL-17 genetic polymorphisms as risk factors for sepsis development in burned patients. Burns 38(2): 208-213, 2012.
143. Gu W, Zeng L, Zhang LY, Jiang DP, Du DY, Hu P, Wang HY, Liu Q, Huang SN and Jiang JX: Association of interleukin 4 -589T/C polymorphism with Th1 and Th2 bias and sepsis in Chinese major trauma patients. J Trauma 71(6): 1583-1587, 2011.
144. Stanilova SA, Miteva LD, Karakolev ZT and Stefanov CS: Interleukin-10-1082 promoter polymorphism in association with cytokine production and sepsis susceptibility. Intensive Care Med 32(2): 260-266, 2006.
145. Arnalich F, Lopez-Maderuelo D, Codoceo R, Lopez J, Solis-Garrido LM, Capiscol C, Fernandez-Capitan C, Madero R and Montiel C: Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 127(2): 331-336, 2002.
146. Dumon K, Rossbach C, Harms B, Gorelov V, Gross-Weege W, Schneider EM, Goretzki PE and Roher HD: Tumor necrosis factor-alpha (TNF-alpha) gene polymorphism in surgical intensive care patients with SIRS. Langenbecks Arch Chir Suppl Kongressbd 115(Suppl 1): 387-390, 1998, (in Germany).
147. Watanabe E, Zehnbauer BA, Oda S, Sato Y, Hirasawa H and Buchman TG: Tumor necrosis factor -308 polymorphism (rs1800629) is associated with mortality and ventilator duration in 1057 caucasian patients. Cytokine 60(1): 249-256, 2012.
148. Lee JH, Lee B, Lee HS, Bae EA, Lee H, Ahn YT, Lim KS, Huh CS and Kim DH: Lactobacillus suntoryeus inhibits proinflammatory cytokine expression and TLR-4-linked NFkappaB activation in experimental colitis. Int J Colorectal Dis 24(2): 231-237, 2009.
149. Pino-Yanes M, Corrales A, Casula M, Blanco J, Muriel A, Espinosa E, Garcia-Bello M, Torres A, Ferrer M, Zavala E, Villar J and Flores C: Common variants of TLR1 associate with organ dysfunction and sustained pro-inflammatory responses during sepsis. PloS one 5(10): e13759, 2010.
150. Woehrle T, Du W, Goetz A, Hsu HY, Joos TO, Weiss M, Bauer U, Brueckner UB and Marion Schneider E: Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans. Cytokine 41(3): 322-329, 2008.